Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MacuSight Inc.

www.macusight.com

Latest From MacuSight Inc.

Otonomy Sustained-Release Gels May Solve Ear Med Delivery Problems

Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.

BioPharmaceutical Clinical Trials

Pfizer withdraws Macugen for DMO in Europe

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO project. The move calls into question not only Pfizer's position in the indication, but also the prospects for a range of other compounds in development for DMO (Table 1)

Cardiovascular Japan

Venture Eyes Ophthalmology--And Likes What It Sees

Ophthalmology has long been a bright spot for venture investors given the potential market size, health care burden, and high unmet medical need associated with many eye diseases. Based on a recent analysis by Start-Up magazine, there is no sign that trend is diminishing. Using Elsevier's Strategic Transactions database, Start-Up found that private backers have poured nearly $1.8 billion into 58 ophthalmology start-ups since 1999, with the money split nearly 50/50 in terms of device and drug investments. This trend is likely to accelerate as a number of new acquirers emerge to play in what was once a niche area.
BioPharmaceutical Medical Device

New appointment at MacuSight

MacuSight (US) has named Gerald Wroblewski vice-president of operations. He previously served as chief operating officer at the start-up medical device company iScience Interventional. MacuSight is developing its proprietary sirolimus product for the treatment of diabetic macular edema, wet age-related macular degeneration and other ophthalmic indications.

Companies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Site Specific
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MacuSight Inc.
  • Senior Management
  • David Weber, PhD, Pres. & CEO
    Joel Naor, MD, CMO
    Shu Kurosaki, Dir., Fin. & Admin.
  • Contact Info
  • MacuSight Inc.
    Phone: (510) 400-1440
    32980 Alvarado-Niles Rd.
    Ste. 846
    Union City, CA 94587
    USA
UsernamePublicRestriction

Register